1-(3-Phenylpropyl)piperazine → 1-[3-(Tert-butoxycarbonyl)-2-(3 pyridyl)thiazolidin-4-ylcarbonyl]-4-(3-phenylpropyl)piperazine
Reaction equation
[C:1]([O:5][C:6]([N:8]1[CH:12]([C:13]([OH:15])=O)[CH2:11][S:10][CH:9]1[C:16]1[CH:17]=[N:18][CH:19]=[CH:20][CH:21]=1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:22]1([CH2:28][CH2:29][CH2:30][N:31]2[CH2:36][CH2:35][NH:34][CH2:33][CH2:32]2)[CH:27]=[CH:26][CH:25]=[CH:24][CH:23]=1>>[C:1]([O:5][C:6]([N:8]1[CH:12]([C:13]([N:34]2[CH2:35][CH2:36][N:31]([CH2:30][CH2:29][CH2:28][C:22]3[CH:27]=[CH:26][CH:25]=[CH:24][CH:23]=3)[CH2:32][CH2:33]2)=[O:15])[CH2:11][S:10][CH:9]1[C:16]1[CH:17]=[N:18][CH:19]=[CH:20][CH:21]=1)=[O:7])([CH3:2])([CH3:3])[CH3:4]Participants
3
Procedure
3-tert-Butoxycarbonyl-2-(3-pyridyl)thiazolidine-4-carboxylic acid (650 mg) and 1-(3-phenylpropyl)piperazine (400 mg) were used as the starting materials and treated in the same manner as in Example 54. Without conversion to the hydrochloride, the product was purified by silica gel column chromatography (eluent ethyl acetate) Thus was obtained 1-[3-(tert-butoxycarbonyl)-2-(3 pyridyl)thiazolidin-4-ylcarbonyl]-4-(3-phenylpropyl)piperazine (560 mg) as an oil.
Workup
- additiontreated in the same manner as in Example 54
- customWithout conversion to the hydrochloride, the product was purified by silica gel column chromatography (eluent ethyl acetate)
Sources & evidence
- ORD record
- ord-4e3f4b96bcc44ca6844dafa91291f264
- Source dataset
- uspto-grants-1991_01
- Patent number
- US04987132
Reaction notes
Loading…